Clinical Trials Logo
  1. Home
  2. Migraine Headache
  3. NCT00460005
  4. Details
NCT00460005 Clinical Trial

Clinical Study Of Migraine Evolution

Migraine Headache Clinical Trial

Official title:
A Multicenter Study to Determine the Clinical Characteristics of the Temporal Aspects of Migraine in a Canadian Population: Clinical Study Of Migraine Evolution (C-SOME)

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00460005
Other study ID # S2W106188
Secondary ID
Status Completed
Phase Phase 4
First received April 12, 2007
Last updated April 14, 2008
Start date January 2006

Study information
Verified date April 2008
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Observational

Clinical Trial Summary

Understanding the speed at which migraine headaches develop is of importance to patients. Determining the proportions in which different headache pain build-up occurs, may provide health care practitioners with valuable information with which to prescribe the most appropriate treatment. Patients who experience a slow pain build-up may gain more benefit from medications which have a slow onset of effect, high tolerability and long action. Conversely, medications with a rapid onset of effect may be of greater benefit to patients who experience rapid onset of migraine pain.

Recruitment information / eligibility
Status Completed
Enrollment 250
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subject is outpatient.

- Subject has a diagnosis of migraine with/without aura according to IHS criteria, of at least 1 years duration.

- Subject is able to comprehend the study procedures and to comply with study requirements.

Exclusion Criteria:

- Subject has other chronic pain condition(s) not associated with migraine

- Subject is unable to understand the schedule/questionnaire.

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
Canada GSK Clinical Trials Call Centre Calgary Alberta
Canada GSK Clinical Trials Call Centre Halifax Nova Scotia
Canada GSK Clinical Trials Call Centre Hamilton Ontario
Canada GSK Clinical Trials Call Centre Longueuil Quebec
Canada GSK Clinical Trials Call Centre Montreal Quebec
Canada GSK Clinical Trials Call Centre Richmond British Columbia
Canada GSK Clinical Trials Call Centre Saint John New Brunswick
Canada GSK Clinical Trials Call Centre Toronto Ontario
Canada GSK Clinical Trials Call Centre Unionville Ontario
Canada GSK Clinical Trials Call Centre Vancouver British Columbia

Sponsors (1)
Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Canada, 

See also
  Status Clinical Trial Phase
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Not yet recruiting NCT05943457 - Vitamin K2 Supplementation in Adult Episodic Migraine N/A
Completed NCT01211145 - Zomig - Treatment of Acute Migraine Headache in Adolescents Phase 4
Completed NCT00530517 - A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack Phase 2
Completed NCT00898677 - Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030) Phase 3
Recruiting NCT06459635 - Migraine Attack Pain Phase Prediction Study
Completed NCT03971071 - A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache Phase 4
Withdrawn NCT02706015 - Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks Phase 3
Terminated NCT02375789 - Intranasal Cooling for Symptomatic Relief of Migraine N/A
Completed NCT02518464 - Ticagrelor Therapy for RefrACTORy Migraine Study Phase 4
Terminated NCT00391755 - A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches Phase 4
Completed NCT03401346 - Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults Phase 1
Completed NCT05085483 - Ketone for Migraine Prevention N/A
Completed NCT01604785 - Low-dose Propofol for Pediatric Migraine Phase 2/Phase 3
Terminated NCT00804973 - Study in Participants With Acute Migraines Headaches Phase 2
Completed NCT03341689 - Psilocybin for the Treatment of Migraine Headache Phase 1
Completed NCT01630044 - Neurostimulation Device for Treatment of Migraine Headache N/A
Active, not recruiting NCT00285402 - Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine Phase 2
Completed NCT00203255 - Clinical Study Examining Use of an Over-the-Counter Supplement for the Prevention of Menstrually-Associated Migraine Headache N/A
Recruiting NCT06046508 - Migraine With Aura and Patent Foramen Ovale: Identification of Biomarkers to Select Patients In Whom Intervention Would Be Beneficial (MANET)